A roundup of notable developments from Japan’s pharmaceutical industry, reported by AnswersNews on 27 July 2026.
Otsuka’s ADHD drug approved in the US
Otsuka Pharmaceutical received US approval for SIMTRIYO (centanafadine), a treatment for attention-deficit/hyperactivity disorder, with launch expected later in 2026. Industry estimates put potential peak annual sales above ¥100 billion.
Pfizer and Eisai to co-promote migraine drug in Japan
Starting September 1, Eisai will co-promote Pfizer’s Nurtec ODT (rimegepant) — the oral CGRP-receptor antagonist covered in our companion article on Japan’s first dual-use migraine drug — expanding its reach through Eisai’s domestic sales network.
Tsumura investing in Ibaraki quality-control facility
Kampo manufacturer Tsumura is investing roughly ¥7 billion in a new quality-control building at its Ibaraki plant, targeted for completion in April 2028.
Other items reported
Nippon Kayaku and Celltrion announced a business development, and J-TEC (Japan Tissue Engineering) and OSB announced a sales partnership; details were not elaborated in the source roundup.
What this is — and isn’t
This is a factual news summary aggregated from trade press, not investment or medical advice.
References
- Answers News, “大塗、米国でADHD药「SIMTRIYO」承認…年内発売へ／ファイザー、片頭痛药「ナルティーク」エーザイとコプロ など|製药業界きょうのニュースまとめ読み（2026年7月27日）” — answers.and-pro.jp/pharmanews/32899/